Related Experiment Video
Updated: Jun 6, 2026
08:28
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
New developments in hormone receptor-positive disease
1Medicine Department, Jules Bordet Institut, Brussels, Belgium. martine.piccart@bordet.be
The Oncologist
|December 9, 2010
Summary
Optimal management of hormone receptor-positive (HR(+)) breast cancer remains challenging. Research is exploring personalized therapies using markers like Ki-67 and CYP2D6 to improve treatment for luminal A and B subtypes.
Area of Science:
- Oncology
- Endocrinology
- Genomics
Background:
- Hormone receptor-positive (HR(+)) breast cancer affects approximately 700,000 women annually worldwide.
- While endocrine therapy has improved outcomes, optimal adjuvant treatment strategies, including chemotherapy thresholds and regimens, are still debated.
- Distinguishing between luminal A and luminal B subtypes is crucial for effective, individualized therapy.
Purpose of the Study:
- To address outstanding challenges in the management of HR(+) breast cancer.
- To explore the role of tumor and host markers in tailoring adjuvant endocrine therapy.
- To highlight the importance of differentiating between luminal A and luminal B breast cancer subtypes.
Main Methods:
- Review of current research on adjuvant therapy for HR(+) breast cancer.
- Investigation of tumor markers (e.g., Ki-67) and host markers (e.g., cytochrome P450 2D6).
- Analysis of emerging data differentiating luminal A and luminal B breast cancer.
Main Results:
- Tumor markers like Ki-67 and host markers like CYP2D6 show potential for personalized adjuvant endocrine therapy.
- Luminal A and luminal B breast cancers represent distinct disease entities requiring different therapeutic approaches.
- Ongoing research aims to refine diagnostic and therapeutic strategies for HR(+) breast cancer.
Conclusions:
- Personalized medicine approaches using molecular markers are key to optimizing HR(+) breast cancer treatment.
- Accurate subtyping of HR(+) breast cancer into luminal A and B is essential for effective therapy selection.
- Further research is needed to establish definitive guidelines for adjuvant chemotherapy and endocrine therapy combinations.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:08Intracellular Hormone Receptors
Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:22Target Cell Response to Hormones
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...